
USD
+$0.00
(+0.00%
)At Close (As of Oct 24, 2025)
$7.26M
Market Cap
-
P/E Ratio
-1.73
EPS
$2.50
52 Week High
$0.52
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $849K |
| Total Revenue | $849K |
| Cost Of Revenue | $240K |
| Costof Goods And Services Sold | $240K |
| Operating Income | -$12M |
| Selling General And Administrative | $7M |
| Research And Development | $4.4M |
| Operating Expenses | $11M |
| Investment Income Net | - |
| Net Interest Income | -$77K |
| Interest Income | - |
| Interest Expense | $77K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $240K |
| Income Before Tax | $12M |
| Income Tax Expense | $12M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$12M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$12M |
| Ebitda | -$11M |
| Net Income | $12M |
| Field | Value (USD) |
|---|---|
| Total Assets | $1.8M |
| Total Current Assets | $385K |
| Cash And Cash Equivalents At Carrying Value | $187K |
| Cash And Short Term Investments | $187K |
| Inventory | - |
| Current Net Receivables | $63K |
| Total Non Current Assets | $1.4M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $135K |
| Other Non Current Assets | - |
| Total Liabilities | $9.6M |
| Total Current Liabilities | $9M |
| Current Accounts Payable | $6.1M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $549K |
| Total Non Current Liabilities | $618K |
| Capital Lease Obligations | $720K |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $720K |
| Other Current Liabilities | $2.3M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | -$7.8M |
| Treasury Stock | - |
| Retained Earnings | -$227M |
| Common Stock | $14K |
| Common Stock Shares Outstanding | $5.3M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$9.1M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $240K |
| Capital Expenditures | $0 |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | $12K |
| Cashflow From Financing | $8M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$12M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $849K |
| Total Revenue | $849K |
| Cost Of Revenue | $240K |
| Costof Goods And Services Sold | $240K |
| Operating Income | -$12M |
| Selling General And Administrative | $7M |
| Research And Development | $4.4M |
| Operating Expenses | $11M |
| Investment Income Net | - |
| Net Interest Income | -$77K |
| Interest Income | - |
| Interest Expense | $77K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $240K |
| Income Before Tax | $12M |
| Income Tax Expense | $12M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$12M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$12M |
| Ebitda | -$11M |
| Net Income | $12M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Brainstorm Cell Therapeutics Inc. (BCLI) is a pioneering biotechnology company dedicated to the advancement of innovative autologous cell therapies targeting neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS). Headquartered in New York, BCLI's lead product, NurOwn, leverages a proprietary stem cell technology platform designed to utilize patients' own cells for therapeutic benefits, with the potential to slow disease progression and improve patients' quality of life. With a robust focus on scientific research and development, Brainstorm aims to establish itself as a frontrunner in the evolving fields of cellular therapy and neurology, offering renewed hope to patients and their families confronting these debilitating diseases.